Federal Register / Vol. 72, No. 51 / Friday, March 16, 2007 / Notices 12619 

past performance of these 

responsibilities when considering 

whether to accept additional topics 

nominated by that organization in 

subsequent years. Specifically, Partners 

are expected to serve as resources to 

EPCs as they develop the evidence 

reports related to the nominated topic; 

serve as external peer reviewers of 

relevant draft evidence reports and 

assessments; and commit to timely 

translation of the EPC reports and 

assessments into their own quality 

improvement tools (e.g., clinical 

practice guidelines, performance 

measures), educational programs, or 

reimbursement policies; and 

dissemination of these derivative 

products to their membership or other 

health care stakeholders, as appropriate. 

AHRQ also is interested in all the uses 

of these derivative products and the 

products’ impact on enhanced health 

care. AHRQ looks to its Partners to 

provide use and impact data on 

products that are based on EPC evidence 

reports and technology assessments. 

4. Topics for Reports 

The EPCs prepare evidence reports, 

technology assessments, and 

comparative and effectiveness reviews 

on topics for which there is significant 

demand for information by health care 

providers, insurers, purchasers, healthrelated societies, and patient advocacy 

organizations. Such topics may include 

the prevention, diagnosis and/or 

treatment of particular clinical and 

behavioral conditions, use of alternative 

or complementary therapies, and 

appropriate use of commonly provided 

services, procedures, or technologies. 

Topics also may include issues related 

to the organization and financing of care 

such as risk adjustment methodologies, 

market performance measures, provider 

payment mechanisms, and insurance 

purchasing tools, as well as 

measurement or evaluation of provider 

integration of new scientific findings 

regarding health care and delivery 

innovations. Previous reports and 

reviews can be found at http:// 

www.ahrq.gov/clinic/epcix.htm and 

http://effectivehealthcare.ahrq.gov/ 

products/progress.cfm. 

AHRQ is very interested in receiving 

topic nominations from professional 

societies and organizations composed of 

members of minority populations, as 

well as topic nominations that have 

significant impact on AHRQ priority 

populations including low-income 

groups, minority groups, women, 

children, the elderly, and individuals 

with special health care needs, such as 

those with disabilities, those who need 

chronic care or end-of-life healthcare, or 

those who live in inner-city and rural 

areas. 

5. Topic Nomination 

Nominations of topics for AHRQ 

evidence reports, technology 

assessments, and comparative 

effectiveness reviews should focus on 

specific aspects of prevention, 

diagnosis, treatment and/or 

management of a particular condition; 

an individual procedure, treatment, or 

technology; or a specific health care 

organizational or financial strategy. The 

processes that AHRQ employs to select 

clinical and behavioral topics as well as 

organization and financing topics 

nominated by the EPCs are described 

below. For each topic, the nominating 

organization must provide the following 

information: 

A. Rationale and supporting evidence 

on the relevance and importance of the 

topic; 

B. Three to five focused questions on 

the topic to be addressed; 

C. Plans for rapid translation of the 

evidence reports and technology 

assessments into clinical guidelines, 

performance measures, educational 

programs, or other strategies for 

strengthening the quality of health care 

services, or plans to inform 

development of reimbursement or 

coverage policies; 

D. Plans for use and/or dissemination 

of these derivative products, e.g., to 

membership and others, if appropriate; 

and, 

E. Process by which the nominating 

organization will measure the use of 

these products and impact of such use. 

6. Topic Selection 

Factors that will be considered in the 

selection of topics for AHRQ evidence 

reports, technology assessments, and 

comparative and effectiveness reviews 

and which should/may be addressed in 

nomination material, include: 

A. Burden of related disease(s) 

including severity, incidence and/or 

prevalence or relevance of the 

organizational/financial topic to the 

general population and/or AHRQ’s or 

the Secretary’s priorities which are 

available at http:// 

www.effectivehealthcare.ahrq.gov; 

B. Total costs associated with a 

condition, procedure, treatment, 

technology, or organization/financial 

topic taking into account the number of 

people needing such care, the unit cost 

of care, and related or indirect costs; 

C. Relevance to the needs of the 

Medicare, Medicaid and other Federal 

health care programs; 

D. Controversy or uncertainty about 

the topic and availability of scientific 

data to support the systematic review 

and analysis of the topic; 

E. Potential for reducing clinically 

significant variations in the prevention, 

diagnosis, treatment, or management of 

a disease or condition; or in changing 

the use of a procedure or technology; 

informing and improving patient and/or 

provider decision making; improving 

health outcomes; and/or reducing costs; 

and, 

F. Nominating organization’s plan to 

disseminate derivative products, 

measure use and impact of these 

products on outcomes, or otherwise 

incorporate the report into its 

managerial or policy decision making. 

7. Submission of Nominations 

Topic nominations for general topics 

should be submitted to Beth A. Collins 

Sharp, Ph.D., R.N., Director, Evidencebased Practice Centers (EPC) Program, 

Center for Outcomes and Evidence, 

AHRQ, 540 Gaither Road, Rockville, MD 

20850. Electronic submissions to 

epc@ahrq.gov are preferred. Topic 

nominations for comparative 

effectiveness reviews should be 

submitted to http:// 

www.effectivehealthcare.ahrq.gov. 

Dated: March 8, 2007. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 07–1236 Filed 3–15–07; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: State Title IV–D Agency 

Caseworkers On-Line Survey. 

OMB No.: New Collection. 

Description: The Office of Child 

Support Enforcement (OCSE) plans to 

reach out to as many State child support 

enforcement caseworkers as possible to 

invite them to participate in a brief online survey. The responses will be used 

to determine if OCSE needs to modify 

the content and the means of 

communicating information and 

training materials used to process child 

support enforcement cases. All 

information will be treated 

confidentially and will not be identified 

by State or e-mail address of 

respondents. Depending on the overall 

response rate to the outreach efforts 

through the title IV–D agencies, the 

actual number of respondents could be 

much lower than the nationwide 


sroberts on PROD1PC70 with NOTICES
12620 Federal Register / Vol. 72, No. 51 / Friday, March 16, 2007 / Notices 

estimate of 60,000 caseworkers used for 

the burden estimates. 

Respondents: State Title IV–D Agency 

Caseworkers. 

ANNUAL BURDEN ESTIMATES

Instrument Number of respondents 

Number of responses per 

respondent 

Average burden hours per 

response 

Total burden 

hours 

Invitation to participate in on-line survey ......................................................... 60,000 1 .1 6,000 

Estimated Total Annual Burden 

Hours: 6,000. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Administration, Office of Information 

Services, 370 L’Enfant Promenade, SW., 

Washington, DC 20447, Attn: ACF 

Reports Clearance Officer. All requests 

should be identified by the title of the 

information collection. E-mail address: 

infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–6974, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

Dated: March 12, 2007. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 07–1231 Filed 3–15–07; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Anti-Infective Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Anti-Infective 

Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on April 11, 2007, from 8:30 a.m. 

to 4 p.m. 

Location: Food and Drug 

Administration, Center for Drug 

Evaluation and Research Advisory 

Committee Conference Room, rm. 1066, 

5630 Fishers Lane, Rockville, MD. 

Contact Person: Lt. Sohail 

Mosaddegh, Center for Drug Evaluation 

and Research (HFD–21), Food and Drug 

Administration, 5600 Fishers Lane (for 

express delivery, 5630 Fishers Lane, rm. 

1093), Rockville, MD 20857, 301–827–

7001, FAX: 301–827–6776, e-mail: 

sohail.mosaddegh@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512530. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The meeting will be open to 

the public from 8:30 a.m. to 9:30 a.m., 

unless public participation does not last 

that long, from 9:30 a.m. to 4 p.m., the 

meeting will be closed to permit 

discussion and review of trade secret 

and/or confidential commercial 

information. 

FDA intends to make background 

material available to the public no later 

than 1 business day before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2007 and scroll down to the 

appropriate advisory committee link. 

Procedure: On April 11, 2007, from 

8:30 a.m. to 9:30 a.m., the meeting is 

open to the public. Interested persons 

may present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before March 28, 2007. 

Oral presentations from the public will 

be scheduled between approximately 

8:30 a.m. and 9:30 a.m. Those desiring 

to make formal oral presentations 

should notify the contact person and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation on 

or before March 21, 2007. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by March 22, 2007. 

Closed Committee Deliberations: On 

April 11, 2007, from 9:30 a.m. to 4 p.m., 

the meeting will be closed to permit 

discussion and review of trade secret 

and/or confidential commercial 

information (5 U.S.C. 552b(c)(4)). 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Sohail 

Mosaddegh at least 7 days in advance of 

the meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: March 8, 2007. 

Randall W. Lutter, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E7–4860 Filed 3–15–07; 8:45 am] 

BILLING CODE 4160–01–S 


sroberts on PROD1PC70 with NOTICES